Coronary Artery Calcium Scoring: Who Should Be Tested, and What Comes Next?

By Parth Parikh, MD; Nishant Shah, MD; Haitham Ahmed, MD, MPH; Paul Schoenhagen, MD; and Maan Fares, MD

The United States has seen a decline in fatal myocardial infarctions, largely thanks to early detection of coronary artery disease. Current guidelines on assessment of cardiovascular risk still rely on the traditional 10-year risk model in clinical practice. However, the predictive value of this approach is only moderate, and many coronary events occur in people considered to be at low or intermediate risk.

Coronary artery calcium scoring is useful in diagnosing subclinical coronary artery disease and has emerged as a means of risk stratification by direct measurement of disease. Many providers are using it, and its relatively low cost and ease of performance have contributed to its widespread use. However, downstream costs, radiation exposure and lack of randomized controlled trials have raised concerns.

This post, excerpted from a recent review article we published in Cleveland Clinic Journal of Medicine (2018;85:707-716), outlines our approach to determining who should be tested with coronary artery calcium scoring, with illustrative case vignettes, and what to do about an elevated score.

Who should be tested?

In the 2013 guideline on assessment of cardiovascular risk from the American College of Cardiology and American Heart Association (ACC/AHA),1 coronary calcium scoring has a class IIB recommendation in scenarios where it may appear that the risk-based treatment decision is uncertain after formal risk estimation has been done. According to a 2017 expert consensus statement2 and 2016 guidelines3 from the Society of Cardiovascular Computed Tomography, a coronary calcium score higher than 100 could be a rationale for starting aspirin therapy, and a score higher than 0 could be a rationale for statin therapy. Current guidelines also mention that the coronary calcium score is comparable to other predictors such as the C-reactive protein level and the ankle-brachial index.

Compared with the ACC/AHA guideline, the Society of Cardiovascular Computed Tomography guidelines and consensus statement added more specifics in terms of using coronary calcium testing for asymptomatic patients at intermediate risk (10-year risk of atherosclerotic cardiovascular disease, 5 to 20 percent) and in selected patients with a family history of premature coronary artery disease and a 10-year risk less than 5 percent.2,3 An earlier (2010) ACC/AHA guideline on cardiovascular risk assessment4 was more specific, offering a class IIA recommendation for patients at intermediate risk (Framingham Risk Score of 10 to 20 percent).

The 2013 ACC/AHA guideline cited cost and radiation exposure as reasons for not giving coronary calcium measurement a stronger recommendation.1 However, as data continue to accumulate, the guidelines may change, especially since low-dose radiation tools are being used for cancer screening (lungs and breast) and since the cost has declined over the past decade.

Our approach

Given the negative predictive value of the coronary calcium score, our approach has been to use this test in asymptomatic patients who are found to be at intermediate risk of atherosclerotic cardiovascular disease based on the ACC/AHA risk calculation1 and are reluctant to start pharmacologic therapy, or who want a more personalized measure of coronary artery disease. This is preceded by a lengthy patient-physician discussion about the risks and benefits of the test.5

The patient’s risk can then be further clarified and possibly reclassified as either low or high if it doesn’t remain intermediate. A discussion can then take place on potentially starting pharmacologic therapy and/or intensive lifestyle modifications.5,6 If an electronic medical record is available, CT results can be shown to the patient in the office to point out coronary calcifications. Seeing the lesions may serve as an additional motivating factor as patients embark on primary preventive efforts.7

Below, we describe cases of what we would consider appropriate and inappropriate use of coronary artery calcium scoring.

Example 1

A 55-year-old man presents for an annual physical and is found to have a 10-year risk of atherosclerotic cardiovascular disease of 7 percent, placing him in the intermediate-risk category. Despite an extensive conversation about lifestyle modifications and pharmacologic therapy, he is reluctant to initiate these measures. He is otherwise asymptomatic. Would calcium scoring be reasonable?

Yes, it would be reasonable to perform coronary artery calcium scoring in an otherwise asymptomatic man to help reclassify his risk for a coronary vascular event. The objective data provided by the test could motivate the patient to undertake primary prevention efforts or, if his score is 0, to show that he may not need drug therapy.

Example 2

A 55-year-old man who has a family history of coronary artery disease, is an active smoker and has diabetes mellitus presents to the clinic with two months of exertional chest pain that resolves with rest. Would coronary artery calcium scoring be reasonable?

This patient is symptomatic and is at high risk of coronary artery disease. Statin therapy is already indicated in the ACC/AHA guidelines, since he has diabetes. Therefore, calcium scoring would not be helpful, as it would not change this patient’s management. Instead, he would be best served by stress testing or coronary angiography based on the stability of his symptoms and cardiac biomarkers.

Example 3

A 30-year-old woman with no medical history presents with on-and-off chest pain at both exertion and rest. Her electrocardiogram is unremarkable, and cardiac enzyme tests are negative. Would coronary calcium scoring be reasonable?

This young patient’s story is not typical for coronary artery disease. Therefore, she has a low pretest probability of obstructive coronary artery disease. Moreover, calcium scoring may not be helpful because, at her young age, there has not been enough time for calcification to develop (median age is the fifth decade of life). Thus, she would be exposed to radiation unnecessarily at a young age.

What to do with an elevated calcium score?

Coronary artery calcification is now being incidentally detected as patients undergo CT for other reasons, such as screening for lung cancer based on the U.S. Preventive Services Task Force guidelines. Patients may also get the test done on their own and then present to a provider with an elevated score.

It is important to consider the entire clinical scenario in such patients and not just the score. If a patient presents with an elevated calcium score but has no symptoms and falls in the intermediate-risk group, there is evidence to suggest that he or she should be started on statin therapy, aspirin therapy or both.

An abnormal test result does not mean that the patient should undergo more-invasive testing such as cardiac catheterization or even stress testing, especially if he or she has no symptoms. However, if the patient is symptomatic, then further cardiac evaluation would be recommended.

Bottom line: Look at the whole picture

Measuring coronary artery calcium has been found to be valuable in detecting coronary artery disease and in predicting cardiovascular events and death. The test is relatively easy to perform, with newer technology allowing for less radiation and cost. It serves as a more personalized measure of disease and can help facilitate patient-physician discussions about starting pharmacologic therapy, especially if a patient is reluctant.

Currently, coronary calcium scoring has a class IIB recommendation in scenarios in which the risk-based treatment decision is uncertain after formal risk estimation has been done according to the ACC/AHA guideline.1 The Society of Cardiovascular Computed Tomography consensus document is more specific in recommending the test in asymptomatic patients in the intermediate-risk group.2

Limitations of calcium scoring include the possibility of unnecessary cardiovascular testing, such as cardiac catheterization or stress testing, being driven by the calcium score alone, as well as the impact of incidental findings. With increased reporting of the coronary calcium score in patients undergoing CT for lung cancer screening, the score should be interpreted in view of the entire clinical scenario.

For the full review article from which this post was excerpted, see Cleveland Clinic Journal of Medicine (2018;85:707-716).

References

1. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Circulation. 2014;129(25 suppl 2):S49–S73. doi:10.1161/01.cir.0000437741.48606.98.
2. Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr. 2017;11:157-168. doi:10.1016/j.jcct.2017.02.010.
3. Hecht HS, Cronin P, Blaha MJ, et al. 2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: a report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology. J Thorac Imaging. 2017;32(5):W54-W66. doi:10.1097/RTI.0000000000000287.
4. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2010;122:2748-2764. doi:10.1161/CIR.0b013e3182051bab.
5. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines. J Am Coll Cardiol. 2015;65:1361-1368. doi:10.1016/j.jacc.2015.01.043.
6. Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacologic and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833-842. doi:10.1016/j.jcmg.2017.01.030.
7. Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing: The EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011;57:1622-1632. doi:10.1016/j.jacc.2011.01.019.

Drs. Parikh and Shah are fellows in the Departments of Internal Medicine and Cardiovascular Medicine at Cleveland Clinic. Drs. Ahmed, Schoenhagen and Fares are staff physicians in the Department of Cardiovascular Medicine.

Image at top reprinted from Cleveland Clinic Journal of Medicine (2018;85:707-716).